Wang Liang, Zhao Robert ChunHua
Center of Tissue Engineering, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, 100005, China.
Sci China C Life Sci. 2009 Jul;52(7):603-9. doi: 10.1007/s11427-009-0091-7. Epub 2009 Jul 30.
Acute graft-versus-host disease (GVHD) occurs after allogeneic hematopoietic stem cell transplant and is a reaction of donor immune cells against host tissues. About 35%-50% of hematopoietic stem cell transplant (HSCT) recipients will develop acute GVHD. It is associated with considerable morbidity and mortality, particularly in patients who do not respond to primary therapy, which usually consists of glucocorticoids(steroids). Most of the available second-line and third-line treatments for steroid-refractory acute GVHD induce severe immunodeficiency, which is commonly accompanied by lethal infectious complications. Mesenchymal stem cells (MSCs) have been shown to mediate immunomodulatory effects. The recently elucidated immunosuppressive potential of mesenchymal stem cells has set the stage for their clinical testing as cellular immunosuppressants, MSCs have been used in patients with steroid-refractory acute GVHD, and encouraging responses have been obtained in many studies. The utility of MSCs for the treatment of GVHD is becoming clear.
急性移植物抗宿主病（GVHD）发生在异基因造血干细胞移植后，是供体免疫细胞对宿主组织的一种反应。约35%-50%的造血干细胞移植（HSCT）受者会发生急性GVHD。它与相当高的发病率和死亡率相关，尤其是在对通常由糖皮质激素（类固醇）组成的初始治疗无反应的患者中。大多数用于治疗类固醇难治性急性GVHD的二线和三线治疗会导致严重的免疫缺陷，这通常伴有致命的感染并发症。间充质干细胞（MSCs）已被证明具有免疫调节作用。间充质干细胞最近被阐明的免疫抑制潜力为其作为细胞免疫抑制剂进行临床试验奠定了基础。MSCs已被用于治疗类固醇难治性急性GVHD的患者，并且在许多研究中都获得了令人鼓舞的反应。MSCs治疗GVHD的效用正变得越来越清晰。
